June 10 (Reuters) - Insmed Inc INSM.O:
INSMED ANNOUNCES POSITIVE TOPLINE RESULTS FROM PHASE 2B STUDY OF TREPROSTINIL PALMITIL INHALATION POWDER (TPIP) AS ONCE-DAILY THERAPY IN PATIENTS WITH PULMONARY ARTERIAL HYPERTENSION
INSMED INC - 35% PLACEBO-ADJUSTED REDUCTION IN PULMONARY VASCULAR RESISTANCE
INSMED INC: STUDY MET PRIMARY AND ALL SECONDARY EFFICACY ENDPOINTS
INSMED INC - TO ENGAGE WITH FDA FOR PHASE 3 TRIAL DESIGN
INSMED INC - RESULTS SHOW SUSTAINED BENEFIT THROUGHOUT 24-HOUR DOSING PERIOD
INSMED: PLANS TO INITIATE PHASE 3 TRIAL IN PATIENTS WITH PH-ILD BEFORE END OF 2025 AND PHASE 3 TRIAL IN PATIENTS WITH PAH IN EARLY 2026
Source text: ID:nPn9JFsFda
Further company coverage: INSM.O
((Reuters.Briefs@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.